A comparison of the efficacy of transforaminal Triamcinolone and Magnesium sulfate injection in chronic low back pain.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201306307984N10

Enrollment

Registered

2017-11-12

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic low back pain. low back pain

Interventions

Intervention 1: In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 150 mg Magnesium Sulfate (Magnesium sulfate 50%, SAMEN, Iran) was injected in the selected level

Treatment - Drugs

In intervention group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 150 mg Magnesium Sulfate (Magnesium sulfate 50%, SAMEN, Iran) was injected in the selected level by a curved blun

In control group 3 ml 0.2% Ropivacaine (Ropivacaina Molteni, Molteni, Italy) plus 20 mg Triamcinolone (Triamcinolone acetonide, EXIR, IRAN) was injected in the selected level by a curved blunt tip 10

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1. Age 20-70 years 2. Pain at least 6 weeks 3. Evidence of Nerve root involvement as disc bulging and/or foraminal stenosis in CT/MRI 4. VAS > 4 5. ASA class I, II 6. Patients’ Informed consent Exclusion criteria: 1. Patients’ with coagulopathy 2. Infection in injection site as Herpetic diseases 3. Anatomical and congenital spine deformity as severe scoliosis 4. Surgical history instrument insertion 5. Psychological severe disorders 6. History of harmful reaction to local anesthetic and steroid. 7. Patients with motor deficit or progressive neural defect. 8. Cancer 9. Neural foramen radiological access difficulty 10. Substance abuse 11. HIV 12. Acute trauma 13. Cauda Equina syndrome 14. More than 3 level abnormalities 15. Absence of Inevitable radicular pain

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Low back pain. Timepoint: Before injection,two weeks,1,3 and 6 month after intervention. Method of measurement: pain score measured with visual analogue scale in Questionnaire.	—

Secondary

Measure	Time frame
Patient performance is based on Oswestry Disability Index, and degree of Leg Raising is based on Straight Leg Raising Test, and possible complications will be recorded. Timepoint: Before injection, two weeks, 1,3 and 6 moth after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farnad Imani

Rasool Akram Medical Center

farnadimani@yahoo.com+98 21 6651 5758

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026